John G. Gorman

John Grant Gorman (born c. 1931) is an Australian physician and medical researcher who co-developed Rho(D) immune globulin, the treatment responsible for the near-total elimination of hemolytic disease of the newborn in the developed world. His central insight — that passive administration of anti-Rh antibodies could prevent maternal immune sensitisation — was described by contemporaries as counterintuitive and by the Lasker Foundation as leading to "the conquest of hemolytic disease of the newborn."

Before Gorman's treatment was approved in 1968, Rh disease killed an estimated 10,000 infants annually in the United States and hundreds of thousands worldwide.

The treatment remains largely unavailable across much of the Global South. Approximately three million at-risk women annually — around 50 percent of those who require it — do not receive Rh immune globulin, resulting in an estimated 160,000 preventable fetal and neonatal deaths and 100,000 cases of lifelong neurological disability each year. Gorman has described this access gap as the central unfinished problem of his career, and continues to advocate for its resolution through the Worldwide Initiative for Rh Disease Eradication (WIRhE).

For his contributions, Gorman shared the 1980 Lasker-DeBakey Clinical Medical Research Award and, in 2024, was appointed an Honorary Companion of the Order of Australia (AC) — Australia's highest civilian honour — for "eminent service to medicine in co-discovering and pioneering a treatment for Rhesus disease for worldwide benefit to humanity."

The problem Gorman set out to solve

Rh disease before prophylaxis Rh disease — formally known as hemolytic disease of the newborn (HDN) due to Rh incompatibility — arises when an Rh-negative mother is exposed to Rh-positive fetal blood cells, typically during delivery, and mounts an immune response producing anti-D antibodies. In subsequent pregnancies carrying Rh-positive fetuses, these antibodies cross the placenta and destroy fetal red blood cells, causing progressive haemolytic anaemia, jaundice, kernicterus (brain damage from bilirubin toxicity), and frequently fetal or neonatal death.

The condition was common: approximately 15 percent of white women carry the Rh-negative blood type, and without intervention, around 10–15 percent of those delivering Rh-positive infants would become sensitised per pregnancy, with cumulative risk rising substantially with each subsequent affected birth.

Research and development of Rho(D) immune globulin

Formulating the theory Gorman's theoretical framework rested on two well-established immunological principles that had not previously been synthesised in this context. First, that passive antibody administration could suppress active immune responses — a phenomenon documented in animal models since the early twentieth century. Second, that the timing of antigen clearance was critical: if fetal red blood cells could be eliminated from the maternal circulation within a sufficiently narrow window following delivery, the immune cascade might never be initiated.

Clinical trials Initial safety trials were conducted on male volunteers at Sing Sing Correctional Facility in the early 1960s, deliberately exposing participants to Rh-positive red blood cells following administration of the immune globulin preparation. The trials confirmed safety and demonstrated effective suppression of antibody formation, establishing proof of concept for human application.

Gorman completed his medical degree at the University of Melbourne in 1954, followed by a residency at St Vincent's Hospital, Melbourne, where early clinical encounters with Rh disease — then responsible for approximately ten percent of neonatal deaths in Melbourne — first directed his interest toward haematology and transfusion medicine.

Awards and recognition

Lasker-DeBakey Clinical Medical Research Award (1980) In 1980, Gorman shared the Lasker-DeBakey Clinical Medical Research Award with Cyril Clarke, Ronald Finn, Vincent Freda and William Pollack. The award citation recognised the group "for illuminating the genetics of the Rh factor and for directing essential research into hemolytic disease of the newborn, and for developing an anti-Rh vaccine, leading to the conquest of hemolytic disease of the newborn."

The investiture was conducted on 30 August 2024 in California by Kevin Rudd, Australia's Ambassador to the United States. Australian Assistant Minister Patrick Gorman stated: "Dr Gorman gave the gift of life to millions. His determination to improve maternal healthcare is an inspiration to us all."

John Gorman Lectureship in Transfusion Medicine In 2016, the Department of Pathology & Cell Biology at Columbia University Irving Medical Center established the John Gorman Lectureship in Transfusion Medicine, endowed in 2018 by Kedrion Biopharma, in recognition of Gorman's contributions to the field during his decades at Columbia. Speakers have included Nobel laureate Peter Agre (2018) and fetal medicine specialist Kenneth J. Moise Jr. (2022).

Since 2018, WIRhE has also hosted the John Gorman Lectureship as part of its BIRTH Congress series, with the fifth iteration held at the BIRTH Congress in Milan in 2022.

Selected bibliography Gorman, J.G., Freda, V.J., & Pollack, W. (1963). "Prevention of sensitization of Rh-negative mothers by Rh-positive infants." Proceedings of the 9th Congress of the International Society of Haematology.